Asthma and Food Allergy Flashcards
Asthma
Respiratory syndrome in which affected patients have episodic shortness of breath, wheezing, coughing (productive or nonproductive), and chest tightness or pain.
These symptoms occur because the airway is obstructed and flow is non-laminar
Atopy
Presdisposition to Th2 responses and IgE production to common, harmless substances
Types on non-allergic asthma
- True non-allergic asthma
- Diseases that mimick allergic and non-allergic asthma
Asthma is not a disease. but a . . .
. . .syndrome
If a patient has asthma symptoms but no known allergies, the diagnosis is . . .
. . . non-allergic asthma until proven otherwise
Symptoms vs signs
- Symptom: Something the patient reports
- Sign: Something the physician observes
Looking for asthma on physical exam
- Tachypnea
- Coughing
- Wheezing / musical respiratory noises
- Signs of other allergic diseases (Dark blue under eyes indicating venous congestion, red, swollen, puffy eyes, edema and pale blue lining nose, eczema, atopic dermatitis, hives, cyanotic fingernails)
The biggest part of diagosing any allergic disease
History!!!!
Clinical tests for allergy
- Aeroallergen skin test: Droplet + skin prick which produces a hive in ~15-20 minutes. Has the advantage of being functional, not just correlative. It is thus a specific test.
- Serology for allergic IgE: May demonstrate possibility of allergy, but not all individuals who are positive will be allergic. Not totally sensitive or specific.
- Inhalant challenge: Patient enters a room with an aeroallergen of known concentration and response is observed.
Quantitative documentation of airway obstruction
- Spirometry
- Set of pulmonary function tests
- Give the forced vital capacity or FVC (total amount of air exhaled on forced exhalation) and the forced expiratory volume in 1 second or FEV1 (the volume exhaled in the first second on forced exhalation)
Healthy FEV1/FVC
~0.8 or 80%
Pathologic demarkation for FEV1/FVC
<0.7
A finding of 0.7 or below is diagnostic for airway obstruction
Reversible airway obstruction diagnosis
This diagnosis is made if the patient has airway obstruction (FEV1/FVC) which then improves (usually by ~12%) following inhalation of a beta-2 receptor agonist
Here the diagnosis of asthma is very likely to be made in context
Differential diagnosis for allergic asthma
- Exercise-induced asthma
- Cold-induced asthma
- Viral infection-induced asthma
- Asthma induced by NSAID
Differential diagnosis for entire asthma syndrome
- COPD (obstruction generally not reversible)
- Cystic fibrosis
- Pulmonary embolism
- Heart failure (leading to pulmonary edema)
- Tumor or stenosis in trachea
- Vocal cord spasm
- GERD and aspiration
- Panic disorder
Potential causes of reduced airflow
- Increased mucus production
- Hypertrophy or spasm of bronchial smooth muscle
- Vascular leakage from airway-associated vessels causing occlusive edema
- Chronic structural changes (thickening of lamina reticularis and bronchial smooth muscle), aka airway remodeling. May start as reversible and become irreversible.
Ohm’s law for fluid mechanics
ΔP = F x R
ie, difference in pressure between x and y is equal to the flow rate between x and y times the resistance between x and y
Resistance in fluid mechanics

airway/bronchial hyper-responsiveness
The bronchoconstrictive and coughing response that is maladaptive in asthma
The most potent bronchoconstricting agents known
The cysteinyl leukotrienes (LTC4, LTD4, and LTE4)
What molecular mechanisms account for bronchoconstriction in asthma?
- IgE-mediated MC degranulation
- Action of histamine and other vascular activators on endothelium, leading to occlusive edema on the bronchus
- Action of cysteinyl leukotrienes on bronchial smooth muscle to tightly constrict it
IL-4
promotes B cells to undergo isotype switching to IgE production and the development of Th2 cells
IL-13
induces B cell isotype switching to IgE synthesis. In addition, IL-13 powerfully stimulates airway mucosal goblet cells to increase mucus production, and it induces “transdifferentiation” other airway cells into new goblet cells. Recall that acute asthma attacks are notable for mucus hypersecretion, and that patients with asthma have airway mucosal goblet cell hypertrophy and hyperplasia
IL-5
arguably the most important cytokine with respect to eosinophils, and is critical to their development and survival. Eosinophil recruitment to and activation in the airways is a classic and important part of allergic asthma. As effector cells in allergic asthma, upon activation, eosinophils release granule contents such as myeloperoxidase and eosinophil peroxidase, leading to the generation of reactive oxygen species that contribute to tissue damage (including to airway epithelial cells, see below) and the further activation of airway mast cells (you can start to see some positive feedback loop here). In addition, eosinophils are important sources of a number of cytokines, such as Transforming Growth Factor (TGF)-beta, IL-4, and IL-13. Eosinophils are very (but not totally) dependent on this cytokine, and it therefore became a rational target for asthma therapy (see below).